An Immuno-oncology Company Developing HER-2+ Gastric and Breast Cancer Therapies

27th Annual ROTH Conference
March 8-11, 2015
Laguna Beach, CA
Disclaimer

This presentation is confidential and has been provided to the recipient for information purposes only, and no representation or warranty, express or implied, is made as to the completeness or accuracy of the information contained herein. This presentation does not constitute an offer to purchase securities in Imugene Limited (the “Company”) or an offer to sell, or a solicitation of an offer to buy any securities in the Company. This presentation neither constitutes nor includes a prospectus to offer securities. Further, this presentation does not constitute an offer by the Company to enter into any transaction with any person or a solicitation of an offer to enter into any transaction with the Company in any manner. This presentation is being made only to qualified institutional buyers and institutions that are accredited investors, as those terms are defined under the U.S. federal securities laws and regulations, pursuant to Section 105(c) of the Jump Start Our Business Startups Act of 2012, for the sole purpose of determining whether such persons might have an interest in a contemplated securities offering. This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company. This presentation is not being distributed through mass communication media or addressed to the general public, or to any person other than the immediate audience that is receiving this presentation in person on the date hereof. This presentation must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person. By attendance at the presentation each recipient agrees to keep the presentation confidential, not to disclose any information included in the presentation in any manner whatsoever and not to disclose the fact of the presentation or any of the terms, conditions, or other facts with respect thereto. No recipient is permitted to utilize this presentation to make an offer, or to solicit any offer, to enter into any transaction whatsoever with or on behalf of the Company.

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.
Corporate Snapshot

- ASX-listed immuno-oncology company (ASX:IMU)
- Developing a B-cell based immunotherapy, known as HER-Vaxx, for HER-2 positive gastric & breast cancer
- Phase 1 trial completed in patients with HER2+/++ breast cancer
- Phase 1b/2 trial to begin 2H 2015
- Technology originates from Medical University of Vienna, one of Europe’s leading cancer institutes
## Investment Highlights

<table>
<thead>
<tr>
<th>Compelling Science</th>
<th>• B-cell peptide cancer immunotherapy that induces an antibody response targeting HER-2 over expressing tumors. Phase 1 complete</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management Team</td>
<td>• Experienced, successful board &amp; management</td>
</tr>
<tr>
<td>Investment to Date</td>
<td>• Approximately $10 million invested to date</td>
</tr>
<tr>
<td>News Flow</td>
<td>• Numerous milestone announcements &amp; valuation inflection points over next 12 months</td>
</tr>
<tr>
<td>Robust IP</td>
<td>• Strong IP with exclusivity until 2030, granted in all major jurisdictions</td>
</tr>
<tr>
<td>Strong Upside</td>
<td>• Targeting improvement over HER-2 antibody, Roche's $6.4 billion Herceptin</td>
</tr>
</tbody>
</table>
**HER-Vaxx: Profile**

- Advanced B-cell vaccine designed to stimulate a patient’s own immune system to repeatedly attack the cancer
- Stimulates a patient’s B cells to produce polyclonal antibodies that target cells with overexpressing HER-2 receptors on their surface
- Targets HER-2 positive cancer - about 20% of patients with gastric cancer are “HER-2 positive”
- HER-Vaxx consists of three peptides from the HER-2 receptor plus an adjuvant
Imugene’s HER-Vaxx: x3 peptides fused together

Polyclonal response

Binding site of HER-2 Receptor

Tumor cell

Binding site of Pertuzumab

Binding site of Trastuzumab
**HER-Vaxx: Mechanism Of Action**

- **HER-Vaxx Immunotherapy**
- **B-cell Activation**
- **HER-Vaxx Antibody Secretion**
- **Tumor Cell**

**3 Peptides**

- P6
- P4
- P7

**Via helper T-cells**
HER-Vaxx: Key Differentiators

- HER-Vaxx peptide sequences identified through extensive computer modelling of HER-2 receptor
- Three sequences selected from analysis: all critical to function of HER-2, including the dimerisation loop of the HER-2 receptor
- Peptides patented worldwide
- When combined with influenza antigens & a virosome, polyclonal response elicited from B cells targets three key areas of HER-2 receptor
- Current commercial antibodies – Herceptin and Perjeta – target two or fewer regions of the HER-2 receptor
- Clinical benefits could include improved efficacy, improved safety, longer administration & lower cost
### Clinical Status: Phase 1 Breast Completed

<table>
<thead>
<tr>
<th>Design</th>
<th>Observations</th>
<th>Clinical Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>• n=10</td>
<td>• Patients developed anti-HER-2 antibodies</td>
<td></td>
</tr>
<tr>
<td>• All metastatic breast cancer patients</td>
<td>• Induction of memory T &amp; B cells post vaccination</td>
<td>1</td>
</tr>
<tr>
<td>• HER-2 +/++</td>
<td>• Reduction in T reg cells post vaccination, indicating strong vaccine response</td>
<td>2</td>
</tr>
<tr>
<td>• Life expectancy &gt; 4 months</td>
<td>• Antibodies induced displayed potent anti-tumor activity</td>
<td></td>
</tr>
<tr>
<td>• Conducted at University of Vienna</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Phase 1b/2 Trial Design – Gastric Cancer

Combined Phase 1b/2 clinical trial planned to confirm safety, evaluate optimal dosing and to show efficacy

Phase 1b lead in to Phase II Trial

• Open label
• 18 patients, x3 groups of 6 patients
• Endpoints:
  – Dose of HER-Vaxx to use in Phase II part of study
  – Safety: any HER-Vaxx toxicity
  – Immunogenicity (anti-HER2/neu antibody titers)
  – Test booster schedule (q 4 weeks or 8 weeks)

Phase 2 Trial

• ~68 patients from Australia and Europe
• Efficacy, safety and immune response
• Randomized, blind, placebo controlled
• Endpoints:
  – Overall survival
  – Progression-free survival
• Secondary endpoint:
  – Immune response
## Robust Intellectual Property

<table>
<thead>
<tr>
<th>Patent Title</th>
<th>Description</th>
<th>Patent number</th>
<th>Expiry date</th>
<th>Territories</th>
</tr>
</thead>
<tbody>
<tr>
<td>‘Vaccine against cancer diseases that are associated with the HER-2/neu Oncogene’</td>
<td>protects specific HER-2 B-cell epitopes</td>
<td>WO02068474</td>
<td>27 Feb 2022</td>
<td>Granted in Australia, Europe, Canada, the USA and Israel</td>
</tr>
<tr>
<td>‘HER-2/neu Multi-peptide Vaccine’</td>
<td>protects specific HER2 B-cell epitopes</td>
<td>WO2007118660</td>
<td>11 April 2027</td>
<td>Granted in Australia, Europe, Israel and pending in Canada</td>
</tr>
<tr>
<td>‘Multi-epitope Vaccine for HER-2/neu-associated Cancers’</td>
<td>claims fusion peptides comprising three noncontiguous B cell epitopes from the extracellular domain of HER-2/neu linked to one another and coupled with a delivery system including a virome</td>
<td>WO2011020604</td>
<td>18 August 2030</td>
<td>Granted in the USA and pending in Europe.</td>
</tr>
<tr>
<td>‘Lyophilisation of virosomes’</td>
<td>granted through an exclusive global license from Pevion Biotech, is for a patent covering the virome vaccine delivery platform, used in the manufacture of “HER-Vaxx”, in the field of oncology</td>
<td>WO2006/069719</td>
<td>21 December 2025</td>
<td>Granted in EP, US, CN, AU, Eurasia and SA</td>
</tr>
</tbody>
</table>
Business Development Opportunity

• Begin awareness campaign for technology with potential partners

• Initiate robust Phase 1b/2 clinical trial

• Seek data-driven partners for remaining development of HER-Vaxx in gastric cancer
  – pivotal trial
  – marketing

• Seek partners for alternative applications of HER-Vaxx
  – additional HER-2 indications
  – additional settings within indications
News Flow & Milestones

1. Complete acquisition of Biolife
2. Appoint manufacturer of fusion peptide
3. Appoint USFDA regulatory consultant
4. Appoint manufacturer of HER-Vaxx
5. Finalize trial protocol 2H2014
6. Appoint CRO to run trial 1H2015
7. Announce preclinical toxicology results 1H2015
8. US FDA IND granted 1H2015
9. Appoint Principal Investigator 1H2015
10. Announce preclinical immunologic results 1H2015
11. Recruit and run lead in Phase 1b trial 2H2015
12. Recruit and run double-blind randomized placebo controlled Phase 2 trial 2H2015
13. Report Phase 1 trial results 2H2015 to 1H2016
14. Report Phase 2 results 2H2017/1H2018
15. License for Phase 3 trial
16. Commercialize
# Recent Licensing Agreements

<table>
<thead>
<tr>
<th>Date</th>
<th>Licensor</th>
<th>Licensee</th>
<th>Technology/ Product</th>
<th>Dev Status</th>
<th>Amount (USD)</th>
<th>Upfront</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>28-Oct-14</td>
<td>F-Star</td>
<td>BMS</td>
<td>FS-102 targeting HER-2</td>
<td>Phase 1 ready</td>
<td>~$50m</td>
<td>$475m</td>
<td></td>
</tr>
<tr>
<td>20-Oct-14</td>
<td>NewLink Genetics</td>
<td>Genentech</td>
<td>NLG919</td>
<td>Phase 1</td>
<td>$150m</td>
<td>$1,150m</td>
<td></td>
</tr>
<tr>
<td>16-Oct-14</td>
<td>Aduro Biotech</td>
<td>Janssen</td>
<td>Several candidates</td>
<td>Discovery</td>
<td>$30m</td>
<td>$847m</td>
<td></td>
</tr>
<tr>
<td>19-Aug-14</td>
<td>Emergent Biosolutions</td>
<td>Morphosys</td>
<td>ES414</td>
<td>Preclinical</td>
<td>$20m</td>
<td>$183m</td>
<td></td>
</tr>
<tr>
<td>18-Jun-14</td>
<td>Cellestis</td>
<td>Pfizer</td>
<td>CAR-T therapy program</td>
<td>Preclinical</td>
<td>$80m</td>
<td>$299m</td>
<td></td>
</tr>
<tr>
<td>27-May-14</td>
<td>CytomX</td>
<td>BMS</td>
<td>Probody platform</td>
<td>Discovery</td>
<td>$50m</td>
<td>$348m</td>
<td></td>
</tr>
<tr>
<td>17-Mar-14</td>
<td>Five Prime Therapeutics</td>
<td>BMS</td>
<td>Immuno-oncology therapies</td>
<td>Discovery</td>
<td>$20m</td>
<td>$351m</td>
<td></td>
</tr>
</tbody>
</table>

Source: Oppenheimer & Co., Company news, internet
Financial Information

- Market capitalization (Mar 3 2015): USD10.4m (AUD13.3m)
- Share price (Mar 3 2015): AUD1.0 cents
- Average daily trade: 1.01m shares
- Shares outstanding: 1,329,912,516
- 2014 loss (June 30 year end): USD1.6m (AUD$2.1m)*
- Cash and equivalents (Dec 31 2014): USD2.3m (AUD$3.0m)*

* USD to AUD conversions made using exchange rate of 0.78 USD: 1.00 AUD
Leadership – Experience and Track Record

Charles Walker
CEO

- Former CEO and CFO of ASX-listed Alchemia
- 20+ years in the life science industry, including a decade in specialist corporate finance in London
- Executed ~50 capital markets transactions as principal and advisor

Paul Hopper
Executive Chairman

- Extensive international & ASX biotech capital markets experience particularly in cancer vaccines
- Head of Life Sciences Desk & Australia Desk at Los Angeles-based investment bank, Cappello Capital Corp

Dr Axel Hoos
Non-Executive Director

- Currently Vice President Oncology R&D at GlaxoSmithKline
- Previously Clinical Lead on Ipilimumab at Bristol-Myers Squibb
- Co-Director of the think-tank Cancer Immunotherapy Consortium; Imugene is his only Board seat worldwide

Otto Buttula
Non-Executive Director

- Extensive & successful experience in investment research & financial services management
- Active & substantial investor in the biotechnology sector with a particular focus on oncology
- Several significant positions in ASX-listed companies including Imugene

Dr Nick Ede
Head of Manufacturing & Operations

- Former CTO Consegna, CEO Adistem Ltd, CEO Mimotopes P/L, COO EQiTX Ltd (ZingoTX & VacTX)
- VP Chemistry Chiron (now Novartis), Research Fellow CRC Vaccine Technology
## Investment Summary

<table>
<thead>
<tr>
<th>Quality Science</th>
<th>Differentiation</th>
<th>Robust IP</th>
<th>Leadership</th>
<th>Best-in-Class Phase 2 Trial</th>
<th>Best-in-Class Phase II Trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>• The subject of numerous peer reviewed published journals</td>
<td>• HER-Vaxx directed at validated target, HER-2</td>
<td>• IP portfolio with 2030 horizon</td>
<td>• Leading clinical &amp; scientific experts; experienced management</td>
<td>• Phase 2 trial designed to be especially robust &amp; big pharma oriented to support potential future partnerships</td>
<td>• Focused 24 month program to deliver results/value inflection</td>
</tr>
<tr>
<td>• Medical University of Vienna, one of Europe’s leading cancer institutes</td>
<td>• HER-Vaxx addresses the multiple targets of Herceptin and Perjeta combined</td>
<td></td>
<td>• Board holds significant shares, aligning interests with shareholders</td>
<td></td>
<td>• Attractively priced to capitalize on upcoming milestones</td>
</tr>
<tr>
<td>• Technology developed over 10 years</td>
<td>• Herceptin sales of USD $6.4bn in 2013</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For personal use only
Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Imugene Limited’s control. Important factors that could cause actual results to differ materially from any assumptions or expectations expressed or implied in this brochure include known and unknown risks. As actual results may differ materially to any assumptions made in this brochure, you are urged to view any forward looking statements contained in this brochure with caution. This presentation should not be relied on as a recommendation or forecast by Imugene Limited, and should not be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.